Latest News

Guangzhou, China – Researchers from the South China University of Technology identified a novel approach to effectively silence the expression of transthyretin (TTR), with potential implications for innovative therapeutic approaches in TTR amyloidosis, including transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The proposed strategy involves stabilizing the G-quadruplex structure—a fundamental genomic structural feature—and...
The burden from activating KIT proto-oncogene (KIT) mutations in patients with advanced systemic mastocytosis (advSM) can be relieved with KIT inhibitors, improving the clinical trajectory of the disease. The protocols for determining staging of SM require updating since these drugs have become available, according to a review published in the International...
Stanford, Calif. – Researchers have identified 22 pesticides consistently associated with the incidence of prostate cancer in the United States, with four of the pesticides also linked with prostate cancer mortality. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. To assess...
PARAMUS, N.J. — Starton Therapeutics Inc., a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced Regional Medical Oncology Center (RMOC) in Wilson, NC as the second site activated in the STAR-LLD Phase 1b clinical trial. The ongoing study evaluates the safety, pharmacokinetics, and efficacy...
In November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic. In this type of cancer...
Amsterdam, The Netherlands – High cholesterol levels are considered to be a risk factor not only for cardiovascular disease including stroke, but also for the development of Alzheimer’s disease. Therefore, many cholesterol lowering drugs, including statins, have been developed in recent years. In addition to the cholesterol reducing effect of...
NEEDHAM, Mass.— Stealth Biotherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for elamipretide for the treatment of Barth syndrome....